{
  "guideline": {
    "id": "PA166104860",
    "name": "Annotation of FDA Label for phenytoin and CYP2C19, CYP2C9, HLA-B",
    "source": "FDA",
    "version": 34,
    "url": "https://www.pharmgkb.org/labelAnnotation/PA166104860",
    "relatedChemicals": [
      {
        "id": "PA450947",
        "name": "phenytoin",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA124",
        "name": "cytochrome P450 family 2 subfamily C member 19",
        "symbol": "CYP2C19"
      },
      {
        "id": "PA126",
        "name": "cytochrome P450 family 2 subfamily C member 9",
        "symbol": "CYP2C9"
      },
      {
        "id": "PA35056",
        "name": "major histocompatibility complex, class I, B",
        "symbol": "HLA-B"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166311452",
      "name": "Recommendation Annotation PA166311452",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452215631,
        "html": "<p>&quot;Patients who are intermediate or poor metabolizers of CYP2C9 substrates (e.g., *1/*3, *2/*2, *3/*3) may exhibit increased phenytoin serum concentrations compared to patients who are normal metabolizers (e.g., *1/*1). Thus, patients who are known to be intermediate or poor metabolizers may ultimately require lower doses of phenytoin to maintain similar steady-state concentrations compared to normal metabolizers...Consider avoiding DILANTIN [phenytoin] as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311463",
      "name": "Recommendation Annotation PA166311463",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452215642,
        "html": "<p>&quot;Patients who are intermediate or poor metabolizers of CYP2C9 substrates (e.g., *1/*3, *2/*2, *3/*3) may exhibit increased phenytoin serum concentrations compared to patients who are normal metabolizers (e.g., *1/*1). Thus, patients who are known to be intermediate or poor metabolizers may ultimately require lower doses of phenytoin to maintain similar steady-state concentrations compared to normal metabolizers.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "1.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311469",
      "name": "Recommendation Annotation PA166311469",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452215648,
        "html": "<p>&quot;Patients who are intermediate or poor metabolizers of CYP2C9 substrates (e.g., *1/*3, *2/*2, *3/*3) may exhibit increased phenytoin serum concentrations compared to patients who are normal metabolizers (e.g., *1/*1). Thus, patients who are known to be intermediate or poor metabolizers may ultimately require lower doses of phenytoin to maintain similar steady-state concentrations compared to normal metabolizers.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "1.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311421",
      "name": "Recommendation Annotation PA166311421",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452215600,
        "html": "<p>&quot;Patients who are intermediate or poor metabolizers of CYP2C9 substrates (e.g., *1/*3, *2/*2, *3/*3) may exhibit increased phenytoin serum concentrations compared to patients who are normal metabolizers (e.g., *1/*1). Thus, patients who are known to be intermediate or poor metabolizers may ultimately require lower doses of phenytoin to maintain similar steady-state concentrations compared to normal metabolizers...Consider avoiding DILANTIN [phenytoin] as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311441",
      "name": "Recommendation Annotation PA166311441",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452215620,
        "html": "<p>&quot;Patients who are intermediate or poor metabolizers of CYP2C9 substrates (e.g., *1/*3, *2/*2, *3/*3) may exhibit increased phenytoin serum concentrations compared to patients who are normal metabolizers (e.g., *1/*1). Thus, patients who are known to be intermediate or poor metabolizers may ultimately require lower doses of phenytoin to maintain similar steady-state concentrations compared to normal metabolizers...Consider avoiding DILANTIN [phenytoin] as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311412",
      "name": "Recommendation Annotation PA166311412",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452215591,
        "html": "<p>&quot;Consider avoiding DILANTIN [phenytoin] as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "0.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311447",
      "name": "Recommendation Annotation PA166311447",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452215626,
        "html": "<p>&quot;Patients who are intermediate or poor metabolizers of CYP2C9 substrates (e.g., *1/*3, *2/*2, *3/*3) may exhibit increased phenytoin serum concentrations compared to patients who are normal metabolizers (e.g., *1/*1). Thus, patients who are known to be intermediate or poor metabolizers may ultimately require lower doses of phenytoin to maintain similar steady-state concentrations compared to normal metabolizers...Consider avoiding DILANTIN [phenytoin] as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311416",
      "name": "Recommendation Annotation PA166311416",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452215595,
        "html": "<p>&quot;Consider avoiding DILANTIN [phenytoin] as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311414",
      "name": "Recommendation Annotation PA166311414",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452215593,
        "html": "<p>&quot;Consider avoiding DILANTIN [phenytoin] as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311462",
      "name": "Recommendation Annotation PA166311462",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452215641,
        "html": "<p>&quot;Patients who are intermediate or poor metabolizers of CYP2C9 substrates (e.g., *1/*3, *2/*2, *3/*3) may exhibit increased phenytoin serum concentrations compared to patients who are normal metabolizers (e.g., *1/*1). Thus, patients who are known to be intermediate or poor metabolizers may ultimately require lower doses of phenytoin to maintain similar steady-state concentrations compared to normal metabolizers...Consider avoiding DILANTIN [phenytoin] as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "1.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311442",
      "name": "Recommendation Annotation PA166311442",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452215621,
        "html": "<p>&quot;Patients who are intermediate or poor metabolizers of CYP2C9 substrates (e.g., *1/*3, *2/*2, *3/*3) may exhibit increased phenytoin serum concentrations compared to patients who are normal metabolizers (e.g., *1/*1). Thus, patients who are known to be intermediate or poor metabolizers may ultimately require lower doses of phenytoin to maintain similar steady-state concentrations compared to normal metabolizers...Consider avoiding DILANTIN [phenytoin] as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "1.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311413",
      "name": "Recommendation Annotation PA166311413",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452215592,
        "html": "<p>&quot;Consider avoiding DILANTIN [phenytoin] as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "0.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311397",
      "name": "Recommendation Annotation PA166311397",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452215576,
        "html": "<p>&quot;Consider avoiding DILANTIN [phenytoin] as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "1.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311415",
      "name": "Recommendation Annotation PA166311415",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450947",
          "name": "phenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452215594,
        "html": "<p>&quot;Consider avoiding DILANTIN [phenytoin] as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": null,
      "title": "Drugs@FDA Drug Product: DILANTIN (phenytoin), NDA008762, Upjohn",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=008762"
    }
  ],
  "version": "2024-02-29-20-19"
}